|
Teva to Market Generic Adenoscan Three Years Early
Teva Pharmaceutical Industries will be able to launch generic Adenoscan under license in September 2012 as part of a settlement agreement with Astellas Pharma and King Pharmaceuticals. The agreement settles litigation filed in the U.S. District Court for the District of Delaware. Astellas and King sued Teva in 2005 after the company filed an abbreviated new drug application seeking approval to market generic Adenoscan (adenosine) before the expiration of King’s ’877 patent in May 2009. Subject to the district court’s approval, the cases will be dismissed and the patents will remain in place. The ’296 patent expires in March 2015. The other terms of the settlement are confidential. |
Register Now
Archives